We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Troponin T Blood Levels Identify Risk of Death Following Surgery

By LabMedica International staff writers
Posted on 11 Jun 2012
A simple blood test can help identify people who are at high risk of dying within the month after noncardiac surgery.

The blood test for the level of troponin T can help physicians target patients who need enhanced observation or interventions. More...
Currently, troponin levels are not commonly measured after surgery.

The results are from the VISION study, the largest international prospective study evaluating complications after surgery. VISION enrolled 15,133 adult patients in North and South America, Asia, Australia, and Europe who had a Troponin T measurement daily during the first three days after surgery. Patients were followed in hospital at 30 days after surgery.

"VISION demonstrated that a simple blood test strongly identifies which noncardiac surgery patients are at high risk of dying in the next 30 days," said Dr. P.J. Devereaux, VISION principal investigator; associate professor of medicine, clinical epidemiology and biostatistics of the Michael G. DeGroote School of Medicine at McMaster University (Hamilton, ON, Canada) and cardiologist at Hamilton Health Sciences (Hamilton, ON, Canada).

Devereaux said the results also demonstrated that most patients did not die until an average of six or more days after their Troponin T blood test was identified as elevated. "This holds out great hope that there is time to intervene."

Currently many laboratories consider a Troponin T measurement >0.04 ng/mL abnormal. VISION demonstrated that Troponin T (TnT) values below the commonly used threshold of 0.04 (i.e., 0.02 and 0.03) were strongly associated with 30-day mortality.

More than 200 million adults worldwide have major noncardiac surgery each year. Despite the benefits of surgery, many patients suffer serious complications and more than one million of those patients die within the first 30 days after surgery. Surgery activates pathways of inflammation, stress, and clotting that predispose the heart to injury. As a result, many patients suffer heart attacks after surgery.

The study was published in the June 2012 Journal of the American Medical Association(JAMA).

Related Links:

Michael G. DeGroote School of Medicine at McMaster University
Hamilton Health Sciences



Gold Member
Neonatal Heel Incision Device
Tenderfoot
Online QC Software
Acusera 24•7
Electrolyte Analyzer
CBS-4000 (CBS-400)
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: The study compares rapid molecular CPE diagnostics, which can return results in about one hour, with culture-based screening, which typically takes about 48 hours (Image credit: Adobe Stock)

Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE

Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read more

Pathology

view channel
Image: The VENTANA PTEN (SP218) RxDx Assay is a qualitative IHC assay for assessing PTEN protein in prostate adenocarcinoma, with staining performed using the OptiView DAB IHC Detection Kit on a BenchMark ULTRA instrument (Photo courtesy of Roche)

New Companion Diagnostic Expands Precision Medicine in Prostate Cancer

Prostate cancer is a leading cancer diagnosis in men and becomes particularly aggressive when it presents as metastatic, hormone-sensitive disease. Tumors with loss of phosphatase and tensin homolog (PTEN)... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.